WO2005115346A3 - Pharmaceutical composition containing risperidone - Google Patents

Pharmaceutical composition containing risperidone Download PDF

Info

Publication number
WO2005115346A3
WO2005115346A3 PCT/IS2005/000014 IS2005000014W WO2005115346A3 WO 2005115346 A3 WO2005115346 A3 WO 2005115346A3 IS 2005000014 W IS2005000014 W IS 2005000014W WO 2005115346 A3 WO2005115346 A3 WO 2005115346A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
composition containing
risperidone
containing risperidone
formulation
Prior art date
Application number
PCT/IS2005/000014
Other languages
French (fr)
Other versions
WO2005115346A2 (en
WO2005115346A9 (en
Inventor
Birkir Arnason
Original Assignee
Actavis Group Hf
Birkir Arnason
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actavis Group Hf, Birkir Arnason filed Critical Actavis Group Hf
Publication of WO2005115346A2 publication Critical patent/WO2005115346A2/en
Publication of WO2005115346A9 publication Critical patent/WO2005115346A9/en
Publication of WO2005115346A3 publication Critical patent/WO2005115346A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A formulation comprising risperidone as an active ingredient, used for generating a tablet by direct compression is provided and a method of manufacturing such formulations. The formulation is particularly suitable for the manufacture of low dose tablets, e.g. having a dose of risperidone in the range of 0.2-1 mg per tablet.
PCT/IS2005/000014 2004-05-28 2005-05-30 Pharmaceutical composition containing risperidone WO2005115346A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IS7290 2004-05-28
IS7290A IS7290A (en) 2004-05-28 2004-05-28 Pharmaceutical formulations containing risperidone

Publications (3)

Publication Number Publication Date
WO2005115346A2 WO2005115346A2 (en) 2005-12-08
WO2005115346A9 WO2005115346A9 (en) 2006-05-18
WO2005115346A3 true WO2005115346A3 (en) 2006-07-06

Family

ID=36715412

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IS2005/000014 WO2005115346A2 (en) 2004-05-28 2005-05-30 Pharmaceutical composition containing risperidone

Country Status (2)

Country Link
IS (1) IS7290A (en)
WO (1) WO2005115346A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
MX337286B (en) 2007-05-25 2016-02-22 Indivior Uk Ltd Sustained delivery formulations of risperidone compounds.
WO2009026621A1 (en) * 2007-08-29 2009-03-05 Alphapharm Pty Ltd Pharmaceutical compound & composition
US20110177137A1 (en) * 2008-09-15 2011-07-21 Intas Pharmaceuticals Limited Novel dosage form of paliperidone and process for preparing the same
CN103356501B (en) * 2012-04-06 2017-08-01 石药集团中奇制药技术（石家庄）有限公司 A kind of Risperidone in Tablets and preparation method thereof
US20140308352A1 (en) * 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
CN115804749A (en) 2013-03-11 2023-03-17 度瑞公司 Injectable controlled release compositions comprising high viscosity liquid carriers

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020193386A1 (en) * 2002-03-28 2002-12-19 Inigo Pfeiffer Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof
WO2003103629A1 (en) * 2002-06-10 2003-12-18 Laboratorios Vita, S. A. Orally disintegrating tablets and process for obtaining them.
WO2004020439A2 (en) * 2002-08-30 2004-03-11 Sunil Sadanand Nadkarni Improved process for preparation of risperidone

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020193386A1 (en) * 2002-03-28 2002-12-19 Inigo Pfeiffer Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof
WO2003103629A1 (en) * 2002-06-10 2003-12-18 Laboratorios Vita, S. A. Orally disintegrating tablets and process for obtaining them.
WO2004020439A2 (en) * 2002-08-30 2004-03-11 Sunil Sadanand Nadkarni Improved process for preparation of risperidone

Also Published As

Publication number Publication date
WO2005115346A2 (en) 2005-12-08
IS7290A (en) 2005-11-29
WO2005115346A9 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
WO2007014124A3 (en) High drug load formulations and dosage forms
WO2006035417A3 (en) Dihydropyrimidine microcapsule - formulations
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
SI2529622T1 (en) Inhibitors of bruton's tyrosine kinase
WO2005097076A3 (en) Low dose pharmaceutical products
HK1096034A1 (en) A solid dosage form comprising a fibrate
WO2006078593A3 (en) Direct compression formulation and process
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
WO2005115346A3 (en) Pharmaceutical composition containing risperidone
WO2005065319A3 (en) Generally linear effervescent oral fentanyl dosage form and methods of administering
IL179718A0 (en) Pharmaceutical composition containing irbesartan
AU2002231654A1 (en) Pharmaceutical paste comprising an acid-labile active ingredient
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
UA96622C2 (en) Solid dosage forms comprising aliskiren obtained by solvent-free granulation process
WO2004078105A3 (en) Fondaparinux sodium composition of high purity, method for production of said composition and pharmaceutical compositions containing the same as active ingredient
CA2445519A1 (en) Method for manufacturing a low dose pharmaceutical composition
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
WO2005065639A3 (en) Novel pharmaceutical compositions
MX2010004556A (en) Pharmaceutical formulation of clavulanic acid.
WO2005004860A3 (en) Novel solid pharmaceutical composition comprising amisulpride
WO2002011694A3 (en) Compositions and dosage forms for application in the oral cavity in the treatment of mykoses
CA2489140A1 (en) Dosage form containing pantoprazole as active ingredient
IL179177A (en) Pharmaceutical composition comprising acyclovir and a delivery agent, a dosage unit, use of acyclovir in the preparation of the pharmaceutical composition, use of the pharmaceutical composition in the preparation of a medicament and a method of preparing the pharmaceutical composition
ZA200506992B (en) Fibrate tablet and method for the production thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGE 13, DESCRIPTION AND PAGE 14, CLAIMS, ADDED

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase